JANIMINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JANIMINE is an oral tablet small-molecule drug approved in 1974 under NDA by Abbott. The mechanism of action and specific indications are not publicly detailed in available data, limiting clinical characterization. This legacy product represents a mature pharmaceutical asset with historical market presence.
LOE Approaching
As JANIMINE approaches loss of exclusivity with moderate competitive pressure (30%), the brand team is likely in transition or defensive mode, with reduced headcount and focus on cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, JANIMINE offers limited career acceleration opportunities. Professionals on this product are typically managing decline, optimizing pricing/access, or transitioning to growth-stage assets.
Brand ManagerField Sales Representative
Worked on JANIMINE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.